je.st
news
RXi Pharmaceuticals Corp (RXII) Upgraded to "Buy" at Zacks Investment Research
2016-02-08 01:00:49| Biotech - Topix.net
The brokerage currently has a $0.25 price target on the biotechnology company's stock. Zacks Investment Research 's price objective would indicate a potential downside of 13.67% from the company's current price.
Tags: buy
research
investment
corp
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||